Rezolute's slogan, "Rezolute is developing transformative therapeutics for rare and metabolic diseases," encapsulates its commitment to pioneering advancements in treating complex medical conditions. The company's United States headquarters serves as the hub for its research, development, and strategic operations. With a sharp focus on leveraging cutting-edge science and technology, Rezolute endeavors to unlock new possibilities in the realm of biopharmaceuticals. To learn more about Rezolute and its groundbreaking initiatives, visit www.rezolutebio.com.
General Information
BounceWatch is an independent company data service, not affiliated with Rezolute, Inc.. To contact Rezolute, Inc., visit rezolutebio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Rezolute, Inc. compare?
A PDF of Rezolute, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Rezolute, Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Rezolute, Inc. on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Rezolute, Inc.
Business keywords: clinical-stage biopharmaceutical company, drug development, metabolic diseases, orphan diseases, therapeutics, antibody therapy, diabetes management, rare diseases, plasma kallikrein inhibitor, clinical trials, biopharma innovation, patient-focused therapies
Funding Rounds & Investors (15)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $56.40M | - |
|
13 Jun 2024 |
| Post IPO Equity | $130.00M | - |
|
01 May 2022 |
| Post IPO Equity | $55.00M | - |
|
13 Oct 2021 |
| Post IPO Equity | $41.00M | 4 | 09 Oct 2020 | |
| Post IPO Equity | $25.00M | 2 | 07 Jan 2019 | |
| Convertible Note | $5.00M | 1 | 03 Apr 2018 | |
| Post IPO Equity | $13.00M | 3 |
Medici Investment, Ildong Pharmaceutical +1
|
17 Jul 2017 |
| Post IPO Equity | $6.70M | - |
|
05 Jun 2017 |
| Post IPO Equity | $4.35M | - |
|
21 Mar 2016 |
| Post IPO Equity | $2.00M | - |
|
16 Apr 2015 |
Rezolute, Inc. Alternatives & Competitors
View All AlternativesDeveloping innovative therapies to treat and cure rare metabolic diseases
Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders
We are a late-stage biopharmaceutical company focused on developing & commercializing products to tr...
FAQ About Rezolute, Inc.
Source: BounceWatch company record for Rezolute, Inc., https://bouncewatch.com/company/rezolute-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.